R
Richard M. Hoffman
Researcher at Roy J. and Lucille A. Carver College of Medicine
Publications - 210
Citations - 10684
Richard M. Hoffman is an academic researcher from Roy J. and Lucille A. Carver College of Medicine. The author has contributed to research in topics: Prostate cancer & Population. The author has an hindex of 49, co-authored 197 publications receiving 9923 citations. Previous affiliations of Richard M. Hoffman include University of Arizona & University of New Mexico.
Papers
More filters
Prof. M Vishwanathan Oration FACTORS AFFECTING COMPLIANCE IN TYPE 2 DIABETIC PATIENTS: EXPERIENCE FROM THE DIABETES OUTCOMES IN VETERANS STUDY (DOVES)
TL;DR: It is my distinct pleasure and privilege to accept the Professor M. Viswanathan Memorial Oration for the Research Society for Study Diabetes in India (RSSDI) and be acknowledged as the “Father of Diabetology” in India.
Journal ArticleDOI
More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades
J. B. Eifler,JoAnn Rudd Alvarez,Tatsuki Koyama,Ralph Conwill,Chad R. Ritch,Karen E. Hoffman,Matthew J. Resnick,David F. Penson,D. A. Barocas,Peter C. Albertsen,Matthew R. Cooperberg,Michael Goodman,Sheldon Greenfield,Ann S. Hamilton,Richard M. Hoffman,Sherrie H. Kaplan,Lisa E. Paddock,Janet L. Stanford,Antoinette M. Stroup,Xiao-Cheng Wu +19 more
TL;DR: Use of watchful waiting or active surveillance was more aligned with disease risk in CEASAR compared to PCOS, suggesting there has been a pivot from watchful waited to active surveillance.
Journal ArticleDOI
Prostate Cancer Testing following a Negative Prostate Biopsy: Over Testing the Elderly
TL;DR: High proportions of men ages 75+ underwent PSA testing and repeat prostate biopsies after an initial negative prostate biopsy, and given the known harms and uncertain benefits for finding and treating localized cancer in elderly men, most continued PSATesting after a negative biopsy is potentially inappropriate.
Journal ArticleDOI
Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study
Richard M. Hoffman,Richard M. Hoffman,Sarah L. Mott,Bradley D. McDowell,Sonia T. Anand,Kenneth G. Nepple,Kenneth G. Nepple +6 more
TL;DR: In this paper, the authors evaluated trends in Expectant Management (EM) and the sociodemographic and clinical factors associated with EM, initiating a National Comprehensive Cancer Network guideline-concordant active surveillance (AS) monitoring protocol, and switching from EM to active treatment (AT).
Early diagnosis of melanoma: what do we know?
TL;DR: The pathophysiology, clinical presentation, epidemiology, and risk factors for melanoma are reviewed, and clinical models for predicting risk and survival are examined, and data on the effectiveness of screening for melanomas is critically appraised.